Clinical Trials
3 trialsNCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03708003 2025-12-30
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
Phase 2 Terminated
NCT03145480 2023-06-01
Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
Northwell Health
Phase 2 Terminated